FDA Oncology

Check out the state of immunotherapy in resectable NSCLC – FDA Oncology

FDA Oncology shared a post on X:

“Check out the state of immunotherapy in resectable NSCLC: This ASCO Ed Book article includes views from academia & FDA. Good warmup for ASCO 24 Education Session ‘Integrating Immunotherapy into Early-Stage Lung Cancer’ on June 2.

→ Ongoing trials of immunotherapy and RT for early stage NSCLC.
→ Clinical implications of recent advances in immunotherapy for resectable NSCLC.
→ Current trial designs assessing immunotherapy in resectable NSCLC: challenges, opportunities.”

View additional information.
Source: FDA Oncology/X
.

academia ASCO 24 ASCO Ed Book cancer Challenges clinical implications early stage NSCLC Education Session FDA FDA Oncology immunotherapy Integrating Immunotherapy into Early-Stage Lung Cancer OncoDaily Oncology ongoing trials opportunities recent advances resectable NSCLC RT trial designs